VoyForums
[ Show ]
Support VoyForums
[ Shrink ]
VoyForums Announcement: Programming and providing support for this service has been a labor of love since 1997. We are one of the few services online who values our users' privacy, and have never sold your information. We have even fought hard to defend your privacy in legal cases; however, we've done it with almost no financial support -- paying out of pocket to continue providing the service. Due to the issues imposed on us by advertisers, we also stopped hosting most ads on the forums many years ago. We hope you appreciate our efforts.

Show your support by donating any amount. (Note: We are still technically a for-profit company, so your contribution is not tax-deductible.) PayPal Acct: Feedback:

Donate to VoyForums (PayPal):

[ Login ] [ Contact Forum Admin ] [ Main index ] [ Post a new message ] [ Search | Check update time | Archives: 1, 2, [3], 4, 5 ]

[ Next Thread | Previous Thread | Next Message | Previous Message ]

Date Posted: 22:14:07 08/04/06 Fri
Author: Daiichi Pharmaceutical Co., Ltd.
Subject: Agreement between Daiichi Pharmaceutical Co., Ltd. and the US Department of Justice

‚r‚…‚10,1999
Daiichi@Pharmaceutical@Co., Ltd

Agreement between Daiichi Pharmaceutical Co., Ltd. and the US Department of Justice


Daiichi today reached a settlement agreement with the US Department of Justice regarding a violation of the US antitrust laws in the sale of the vitamin, Calcium Pantothenate (Calpan). Calpan is mainly used in food products and animal feeds.

The US Department of Justice has investigated Daiichi together with foreign manufacturers of Calpan for impeding fair competition during the period from 1991 to 1998. As a result of the settlement, Daiichi agreed to pay a fine of USD 25 million (approximately Yen 2.8 billion) with respect to unlawful conduct in its International Business Division. Daiichi has cooperated with the US Department of Justice in its investigation and will continue to do so.

Regarding civil claims brought by individual and corporate buyers in the US seeking to recover damages, Daiichi is endeavouring to work to resolve these claims. In addition, Daiichi is under investigation in Canada and the European Union.

To respect and comply with the law is a principal policy of Daiichi's management which has made effort to educate all of its officers and employees. Above all, as to free and fair competition, it has educated its personnel not only with the ethical code of the pharmaceutical industry but also with its Internal Antitrust Compliance Policy and Guidelines for Businesses to completely comply with the antitrust laws. Daiichi deeply regrets the occurrence of wrongdoings.

Meanwhile, Daiichi is taking measures to prevent the recurrence of any violation and ensure future compliance with the antitrust laws, specifically, it is preparing "Guidelines of Actions for Compliance" with which all officers and employees will be reeducated. Furthermore, the Company has appointed a managing director at the Company to be in charge of corporate ethics and clearly designated a division to promote compliance with laws.






Website - http://ir.daiichipharm.co.jp/TopU,itemId,122799,event,ViewWhatsNew,locale,en_US.html

[ Next Thread | Previous Thread | Next Message | Previous Message ]

Replies:

[ Contact Forum Admin ]

Forum timezone: GMT-8
VF Version: 3.00b, ConfDB:
Before posting please read our privacy policy.
VoyForums(tm) is a Free Service from Voyager Info-Systems.
Copyright © 1998-2019 Voyager Info-Systems. All Rights Reserved.